Scarica l'app Stockscreener
3.40
2.72%
0.09
Vigil Neuroscience Inc Borsa (VIGL) Ultime notizie
Ensign Peak Advisors Inc Buys 166,442 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Yahoo Finance
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com South Africa
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - StockTitan
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - StockTitan
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Trading 5% Higher - MarketBeat
Neurodegenerative Disorder Therapeutics Market Insights Discussed Regarding Size And Outlook 2024-2033 - WhaTech
A stock that deserves closer examination: Vigil Neuroscience Inc (VIGL) - US Post News
You might want to take a look at Vigil Neuroscience Inc (VIGL) now - SETE News
Vigil Neuroscience to Present at Upcoming September Investor Conferences - GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences - StockTitan
Vanguard Group Inc. Acquires 95,276 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Q3 2024 EPS Estimates for Vigil Neuroscience, Inc. Decreased by Analyst (NASDAQ:VIGL) - MarketBeat
Research Analysts Offer Predictions for Vigil Neuroscience, Inc.’s Q3 2024 Earnings (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by HC Wainwright - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in July - MarketBeat
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock - Investing.com India
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com Canada
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com UK
Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $16.00 by Analysts at Guggenheim - Defense World
HC Wainwright Analysts Cut Earnings Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
FY2027 EPS Estimates for Vigil Neuroscience, Inc. Reduced by HC Wainwright (NASDAQ:VIGL) - Defense World
FY2024 Earnings Forecast for Vigil Neuroscience, Inc. (NASDAQ:VIGL) Issued By Wedbush - Defense World
Guggenheim Trims Vigil Neuroscience (NASDAQ:VIGL) Target Price to $16.00 - MarketBeat
Vigil Neuroscience's (VIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024 - MSN
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024 - InvestorPlace
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics - GlobeNewswire
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics - StockTitan
Vigil Presents Data on its Small Molecule TREM2 Agonist - GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC) - Yahoo Finance
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 48.4% in July - Defense World
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):